Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay
Zilei Xia(University of Arizona), Jun Wang(Rutgers Sexual and Reproductive Health and Rights), M. Sacco(University of South Florida), Julia A. Townsend(University of Arizona), Yanmei Hu(University of Arizona), Naoya Kitamura(University of Arizona), Chunlong Ma(University of Arizona), Mandy Ba(University of Arizona), Tommy Szeto(University of Arizona), Fushun Zhang(The University of Texas at San Antonio Health Science Center), Michael T. Marty(University of Arizona), Yu Chen(University of South Florida), Xiujun Zhang(Tianjin University of Traditional Chinese Medicine), Yan Xiang(Sichuan University), Xiangzhi Meng(University of California, Los Angeles)
Cited by 8
Related Papers
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M <sup>pro</sup> and cathepsin L
|Science Advances|2020|400
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
|Nature|2021|216
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
|ACS Central Science|2021|200
The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
|Emerging Microbes & Infections|2021|190
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
|Journal of Medicinal Chemistry|2021|168